· Published by Health Canada · Official notice
Taro Pharmaceuticals Inc. is recalling five lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100), due to the potential presence of particulate matter.
Taro-Zoledronic acid injection 5mg/100mL, used for osteoporosis and Paget’s disease
Check the lot number on your product or contact your pharmacist to determine whether any of your products are subject to this recall. If you have a recalled product do not take the medication and, contact your healthcare provider to obtain a replacement product. If you have taken a recalled product and have any concerns about your health, contact your healthcare provider.
Health Canada is advising Canadians that Taro Pharmaceuticals Inc. is recalling five lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100) because of the potential presence of particulate matter in the drug. Zoledronic acid is used to treat and prevent osteoporosis, as well as to treat Paget’s disease (i.e., a condition that causes bone deformities).
If injected, the presence of particles could cause inflammation or irritation of veins that could cause blockage of blood vessels. In the most serious of cases it could cause lung damage, serious allergic reactions or formation of blood clots.
All lots of the drug distributed by Taro Pharmaceuticals Inc. between August 1, 2018, and December 24, 2019, are affected by the recall. Health Canada is monitoring the recall, and should the Department become aware of additional safety information, it will take appropriate action and inform Canadians as necessary.
Patients who are taking, or who have taken, Taro-Zoledronic acid injection 5mg/100mL, or patients who have obtained this product from a pharmacy.
| Company | Product Name/Active Pharmaceutical Ingredient (API) | DIN | Strength | Lot | Expiry |
|---|---|---|---|---|---|
| Taro Pharmaceutical Inc. | Taro-Zoledronic acid injection | 02415100 | 5mg/100mL | JKT1520A | April 2020 |
| JKT1580A | May 2020 | ||||
| JKT1581A | May 2020 | ||||
| JKT1642A | May 2020 | ||||
| JKT1643A | May 2020 |
Health Canada is monitoring the recall and verifying that the company has effectively addressed the issue. Should additional safety concerns be identified, Health Canada will take appropriate action and inform Canadians as necessary.